vemurafenib
Commercial- Indications
- Melanoma
Company intelligence / Profile preview
Plexxikon Inc.
Berkeley, California, United Statesplexxikon.com ↗
- Ownership
- Private
- Employees
- ~60
- Development stage
- Commercial
01
Overview
Plexxikon developed two FDA-approved cancer therapies: Zelboraf (vemurafenib) for melanoma and Turalio for rare benign tumors. The company permanently closed its office and research facility on March 31, 2022.
- Therapeutic areas
- CardiovascularImmunologyOncologyRare DiseasesNeurology
- Modalities
- Small moleculeskinase inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Genentech/RocheWyeth Pharmaceuticals
Beyond the preview
Go deeper on Plexxikon Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Plexxikon Inc..